Shinichiro Motohashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shinichiro Motohashi has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Atsushi Onodera
Institute for Advanced Academic Research, Chiba University, Chiba, Japan
59 shared publications - Toshinori Nakayama
Department of Immunology, Graduate School of Medicine Chiba University Chiba Japan
38 shared publications - Kiyoshi Hirahara
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
34 shared publications - Motoko Y. Kimura
Synergy Institute for Futuristic Mucosal Vaccine Research and Development, Chiba University, Chiba, Japan
34 shared publications - Ichita Hasegawa
Department of Experimental Immunology, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, Japan
33 shared publications - Masahiro Kiuchi
Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan
33 shared publications
Latest Publications
- Open Access
- 20 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e016268
HER2 CAR-expressing iPSC-derived iNKT cells exhibit multifaceted immunomodulatory functions beyond direct tumor killing
- 20 October 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (10) , e016268
Open AccessHER2 CAR-expressing iPSC-derived iNKT cells exhibit multifaceted immunomodulatory functions beyond direct tumor killing
- Open Access
- 25 August 2026
- Published by Wiley in Cancer Science
Psychological Stress Promotes Tumor Growth in Hepatocellular Carcinoma Models Through Myeloid Signaling
Psychological stress has long been implicated in cancer progression, yet the underlying biological pathways remain incompletely understood. In particular, the influence of stress on myeloid cells remains poorly explored. Here, we demonstrate that restraint stress accelerates hepatocellular carcinoma (HCC) progression through coordinated regulation of macrophages and neutrophils. Across sexes and strains, stressed mice exhibited enhanced tumor growth accompanied by marked neutrophil infiltration and elevated expression of neutrophil‐attracting chemokines. Integrative analyses combining single‐cell transcriptomics and in vitro experiments identified macrophages as the dominant producers of these chemokines and revealed that β 2 ‐adrenergic receptor signaling drives Cxcl2 expression in response to stress‐related catecholamines. In parallel, neutrophils themselves were reprogrammed toward an immunosuppressive phenotype under stress. This phenotypic shift was already evident in bone marrow neutrophils, where activation of the hypothalamic–pituitary–adrenal (HPA) axis led to corticosterone‐driven, glucocorticoid receptor–dependent induction of an immunosuppressive gene. These findings define a coordinated neuroendocrine mechanism in which psychological stress remodels myeloid cell function through sympathetic and HPA axis signaling, thereby fostering an immunosuppressive tumor microenvironment that promotes HCC progression. While pharmacologic blockade of either axis may mitigate stress‐driven tumor growth, our findings suggest that non‐pharmacological stress‐reduction strategies could represent a valuable complementary approach in managing HCC progression.
- 25 August 2026
- Published by Wiley in Cancer Science
Open AccessPsychological Stress Promotes Tumor Growth in Hepatocellular Carcinoma Models Through Myeloid Signaling
Psychological stress has long been implicated in cancer progression, yet the underlying biological pathways remain incompletely understood. In particular, the influence of stress on myeloid cells remains poorly explored. Here, we demonstrate that restraint stress accelerates hepatocellular carcinoma (HCC) progression through coordinated regulation of macrophages and neutrophils. Across sexes and strains, stressed mice exhibited enhanced tumor growth accompanied by marked neutrophil infiltration and elevated expression of neutrophil‐attracting chemokines. Integrative analyses combining single‐cell transcriptomics and in vitro experiments identified macrophages as the dominant producers of these chemokines and revealed that β 2 ‐adrenergic receptor signaling drives Cxcl2 expression in response to stress‐related catecholamines. In parallel, neutrophils themselves were reprogrammed toward an immunosuppressive phenotype under stress. This phenotypic shift was already evident in bone marrow neutrophils, where activation of the hypothalamic–pituitary–adrenal (HPA) axis led to corticosterone‐driven, glucocorticoid receptor–dependent induction of an immunosuppressive gene. These findings define a coordinated neuroendocrine mechanism in which psychological stress remodels myeloid cell function through sympathetic and HPA axis signaling, thereby fostering an immunosuppressive tumor microenvironment that promotes HCC progression. While pharmacologic blockade of either axis may mitigate stress‐driven tumor growth, our findings suggest that non‐pharmacological stress‐reduction strategies could represent a valuable complementary approach in managing HCC progression.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- 24 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (30) , eadx9864
Distinct thymic pDC populations promote tumor immune tolerance through complementary mechanisms
Thymic central tolerance is crucial for preventing autoimmunity, but its contribution to tumor immune evasion remains poorly understood. Here, we demonstrate that plasmacytoid dendritic cells (pDCs) in the thymus have two distinct subsets, accumulating in the thymus of tumor-bearing mice, contributing to immune tolerance through clonal deletion of tumor-specific T cells and reducing newly generated T cells. Mechanistically, common dendritic cell progenitor-derived pDCs (CDP-pDCs) capture tumor antigens and migrate to the thymus in a CCR9-dependent manner, where they present these antigens to induce clonal deletion of tumor-specific T cells. Concurrently, tumor progression inhibits T cell generation by promoting the accumulation of common lymphoid progenitor–derived pDCs (CLP-pDCs) within the thymus, which further produce type I interferon to alter thymic function. CCR9 deficiency prevents thymic accumulation of both pDCs, enhancing antitumor immunity and reducing tumor growth. Our findings reveal a previously unrecognized mechanism by which tumors hijack the physiological system to establish central tolerance against peripheral antigens, thereby promoting tolerance against themselves.
- Open Access
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- 10 April 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (15) , eadw1038
Open AccessCD69 regulates the tissue dynamics of epigenetically imprinted memory CD4 + T cells
Tissue-resident memory T cells (T RM cells) reside in nonlymphoid tissues and provide the first line of defense against pathogens. A subset of T RM cells can egress from nonlymphoid tissues into the circulation. However, the functional consequences and the extent of epigenetic imprinting in recirculating T RM cells remain unknown. We herein demonstrate that in CD4 + T RM cells, the CD69-S1PR1 axis controls tissue residency and that interrupting this axis results in ablation of lung CD4 + T RM cells. A subpopulation of CD69 + CD4 + T RM cells reentered circulation via lymphatic vessels, where they epigenetically maintained the characteristics of T RM cells in both mice and humans. Circulating Ex-lung-T RM cells in mice caused enhanced skin inflammation compared to circulating memory cells. Furthermore, we identified GPR183 and CD161 as potential markers of Ex-T RM in human peripheral blood mononuclear cells. In chronic inflammatory diseases, the transposition of allergic inflammation to multiple tissues may therefore occur via recirculation of tissue-imprinted memory CD4 + T cells.
- Open Access
- 25 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC
Small cell lung cancer (SCLC) is aggressive with limited treatment options, requiring new therapies. Lysine-specific histone demethylase 1 A (LSD1) maintains neuroendocrine state by repressing NOTCH/TGF-β signaling; their reactivation suppresses proliferation and induces differentiation. However, mechanisms of LSD1 inhibition and chemoresistance remain unclear. Here we developed TAS1440, a histone H3-competitive LSD1 inhibitor, using structure-based engineering to improve specificity and reduce off-target effects. Unlike irreversible inhibitors targeting the flavin adenine dinucleotide site, TAS1440 non-covalently targets the H3-binding pocket to enhance safety and efficacy. TAS1440 suppressed proliferation in INSM1/ASCL1-high SCLC-A cells and induced tumor regression in xenografts. TAS1440 acts through dual mechanisms: inhibiting LSD1 activity and disrupting LSD1-repressive complexes, remodeling histone marks and activating transcription factors INSM1 and SMAD2. These actions reprogram tumor-suppressive TGF-β/NOTCH signaling, supporting TAS1440 as epigenetic therapy for SCLC. Loss of LSD1 enzymatic activity or INSM1 knockout abrogated TAS1440 effects, defining its mode of action and chemoresistance. These findings support TAS1440 as a next-generation epigenetic therapy candidate for INSM1-high SCLC-A.
- 25 March 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessLSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC
Small cell lung cancer (SCLC) is aggressive with limited treatment options, requiring new therapies. Lysine-specific histone demethylase 1 A (LSD1) maintains neuroendocrine state by repressing NOTCH/TGF-β signaling; their reactivation suppresses proliferation and induces differentiation. However, mechanisms of LSD1 inhibition and chemoresistance remain unclear. Here we developed TAS1440, a histone H3-competitive LSD1 inhibitor, using structure-based engineering to improve specificity and reduce off-target effects. Unlike irreversible inhibitors targeting the flavin adenine dinucleotide site, TAS1440 non-covalently targets the H3-binding pocket to enhance safety and efficacy. TAS1440 suppressed proliferation in INSM1/ASCL1-high SCLC-A cells and induced tumor regression in xenografts. TAS1440 acts through dual mechanisms: inhibiting LSD1 activity and disrupting LSD1-repressive complexes, remodeling histone marks and activating transcription factors INSM1 and SMAD2. These actions reprogram tumor-suppressive TGF-β/NOTCH signaling, supporting TAS1440 as epigenetic therapy for SCLC. Loss of LSD1 enzymatic activity or INSM1 knockout abrogated TAS1440 effects, defining its mode of action and chemoresistance. These findings support TAS1440 as a next-generation epigenetic therapy candidate for INSM1-high SCLC-A.
- Open Access
- 26 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342387
A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol
Natural killer T (NKT) cells show intense tumor-killing activity through direct and indirect pathways. However, humans have less than 0.01% of NKT cells in the peripheral blood, making it difficult to apply NKT cells for cancer treatment. We have successfully produced invariant NKT cells derived from induced pluripotent stem cells (iPSC-iNKT cells) and demonstrated the tolerability of this product in a previous phase 1 clinical trial. Although the iPSC-iNKT cells showed substantial anti-tumor activity against various tumor cell types when combined with α-Galactosylceramide-pulsed autologous dendritic cells (DC/Gal) in non-clinical experiments, the tolerability of this combination therapy for humans has not demonstrated yet. Thus, we planned this first-in-human phase 1 open-label clinical trial to demonstrate data on tolerability and safety, as well as explore the immunological changes that occur following this combination treatment. We hypothesize that the sequential induction of nasal submucosal DC/Gal injection and intra-arterial administration of the iPSC-iNKT cells is tolerable and has a favorable safety profile for cancer patients. This trial provides vital and fundamental information for next-phase clinical trials and future applications of iPSC-iNKT cells for various cancer patients (jRCTa030220741; URL: https://jrct.mhlw.go.jp/en-latest-detail/jRCTa030220741 ).
- 26 February 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (2) , e0342387
Open AccessA phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol
Natural killer T (NKT) cells show intense tumor-killing activity through direct and indirect pathways. However, humans have less than 0.01% of NKT cells in the peripheral blood, making it difficult to apply NKT cells for cancer treatment. We have successfully produced invariant NKT cells derived from induced pluripotent stem cells (iPSC-iNKT cells) and demonstrated the tolerability of this product in a previous phase 1 clinical trial. Although the iPSC-iNKT cells showed substantial anti-tumor activity against various tumor cell types when combined with α-Galactosylceramide-pulsed autologous dendritic cells (DC/Gal) in non-clinical experiments, the tolerability of this combination therapy for humans has not demonstrated yet. Thus, we planned this first-in-human phase 1 open-label clinical trial to demonstrate data on tolerability and safety, as well as explore the immunological changes that occur following this combination treatment. We hypothesize that the sequential induction of nasal submucosal DC/Gal injection and intra-arterial administration of the iPSC-iNKT cells is tolerable and has a favorable safety profile for cancer patients. This trial provides vital and fundamental information for next-phase clinical trials and future applications of iPSC-iNKT cells for various cancer patients (jRCTa030220741; URL: https://jrct.mhlw.go.jp/en-latest-detail/jRCTa030220741 ).
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S2 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S3 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Figure S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes
Table S1 from CD69 Imposes Tumor-Specific CD8+ T-cell Fate in Tumor-Draining Lymph Nodes